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SUMMARY  
 
Background: Vinorelbine chemotherapy with G-CSF stimulation is a widely applied non-
myelosuppressive mobilization regimen in Switzerland for myeloma patients, but its 
neurotoxic potential limits its use in patients with bortezomib induced polyneuropathy.  
Methods: In this single-center study, we alternatively evaluated safety and effectiveness of 
gemcitabine chemotherapy with G-CSF for mobilization of autologous stem cells.  
Results: Between 03/2012 and 02/2013, all bortezomib pretreated myeloma patients planned 
to undergo first-line high-dose melphalan chemotherapy received a single dose of 
1250mg/m2 gemcitabine, with G-CSF started on day four. The 24 patients in this study have 
received a median of four cycles of bortezomib-dexamethason based induction. Bortezomib-
caused polyneuropathy was identified in 21 patients (88%) by clinical evaluation and a 
standardized questionnaire. Administration of gemcitabine mobilization did not induce novel 
or aggravate preexisting neuropathy. Stem cell mobilization was successful in all 24 patients, 
with a single day of apheresis being sufficient in 19 patients (78%). The median yield was 
9.51 x 106 CD34+ cells/kg. Stem collection could be accomplished at day 8 in 67%.  
Conclusion: Our data suggest that single-dose gemcitabine together with G-CSF is an 
effective mobilization regimen in myeloma patients and a safe alternative non-
myelosuppressive mobilization chemotherapy for myeloma patients with bortezomib induced 
polyneuropathy.  
 
 
 
KEY WORDS: mobilization; stem cells; myeloma; polyneuropathy; gemcitabine; bortezomib; 
neurotoxicity; autologous; transplant. 
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INTRODUCTION 
 
Significant advances have been reported in the treatment of myeloma patients in the last 
decades. The introduction of proteasome inhibitors and immunomodulatory compounds for 
induction treatment, high-dose chemotherapy (HDCT) followed by autologous stem cell 
transplantation (ASCT) for consolidation, and subsequent maintenance treatment with 
lenalidomide or bortezomib have increased remission and survival rates in myeloma patients 
(Bladé et al, 2005; Fernand et al, 2005; Giralt et al, 2011; Harrousseau et al, 2009; Ludwig et 
al, 2010; Rajkumar, 2011). Noteworthy, a number of studies identified an independent benefit 
of first-line HDCT with ASCT also in the era of novel agents, which was further enhanced by 
maintenance treatment after HDCT (Bladé et al, 2005; Fernand et al, 2005; Giralt et al, 2011; 
Harrousseau et al, 2009). These observations indicate that ASCT continues to be a 
component of the first-line treatment algorithm for young and fit myeloma patients 
(Harrousseau et al, 2009; Ludwig et al, 2010). 
The optimal strategy to mobilize autologous stem cells from the bone marrow to the 
peripheral blood remains an issue of ongoing controversy (Giralt et al, 2011). Repetitive 
applications of the granulocyte colony-stimulating factor (G-CSF) alone can effectively 
mobilize peripheral CD34+ cells, whereas the combination of G-CSF with chemotherapy is 
usually associated with a more potent recruitment of CD34+ cells from the bone marrow 
niche. The additional administration of the expensive stem cell mobilizing compound 
plerixafor represents a rescue strategy for patients failing such mobilization strategies.  
Based on the considerations above, the combined use of chemotherapy and G-CSF 
is a widely used concept. While high-dose cyclophosphamide with G-CSF is commonly given 
for chemotherapy mobilization, the administration of a single dose of non-myelosuppressive 
chemotherapy with vinorelbine (35mg/m2) together with G-CSF started on day 4 is the 
standard mobilization regimen in Switzerland since more than a decade (Bargetzi et al, 2003; 
Heizmann et al, 2009; Samaras et al, 2015; Schmid et al, 2015). Its obvious advantages 
compared to cyclophosphamide treatment comprise a highly predictable stem cell collection 
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at day 8, the entirely ambulatory concept, and the lack of infectious and toxic complications 
notoriously following cyclophosphamide mobilization (Bargetzi et al, 2003; Heizmann et al, 
2009; Samaras et al, 2015; Schmid et al, 2015). 
With the predominant use of bortezomib during induction treatment and with 
chemotherapy-induced polyneuropathy (CIPN) as its major and often limiting side effect, the 
subsequent use of vinorelbine for mobilization has become increasingly problematic because 
of its added neurotoxicity (Argyriou et al, 2008; Carlson et al, 2011; Delforge et al, 2010; 
Keller et al, 2015; Koeppen et al, 2014; Mohty et al, 2010; Richardson et al, 2006; Swain et 
al, 2008). Clinically significant induction of novel - as well as aggravation of bortezomib 
induced - CIPN following mobilization treatment with a single dose of vinorelbine in myeloma 
patients has recently been reported by our group (Keller et al, 2015). These facts identified a 
need for an alternative non-neurotoxic mobilization chemotherapy, while preserving the 
advantages of a non-myelosuppressive strategy.  
Gemcitabine has been previously used for stem cell mobilization as a part of 
polychemotherapy regimens in Hodgkin lymphoma patients (Suyani et al, 2011). However, 
its use as monochemotherapy for mobilization has not been reported so far. In this study, we 
investigated the safety and effectiveness of gemcitabine together with G-CSF for the 
mobilization of autologous stem cells in myeloma patients after bortezomib/dexamethasone-
based induction treatment. 
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PATIENTS AND METHODS 
 
Patients and study design 
This is a single-center prospective study analyzing all consecutive myeloma patients 
undergoing first-line consolidation treatment with high-dose melphalan chemotherapy 
(HDCT) and autologous stem cell transplantation (ASCT) between 03/2012 and 02/2013. 
Patients must have been treated with a bortezomib/dexamethasone-based induction 
regimen, the age neded to be below 71 years, and a minimum renal function with a kreatinin 
clearance of 40ml/min and neutrophils above 1.0 G/L were required. Clinical characteristics 
and treatment details of the patient cohort are depicted in Table 1. The local ethics 
committee of Berne, Switzerland with decision #143/2014 approved this study.  
Data sources were medical records of the patients. Neuropathy was assessed by two 
independent investigators, with T.P. having been one of them for all study patients. In 
addition, a standardized questionnaire was filled out by all study patients. The questionnaire 
assessed signs and treatment of neuropathy as well as the subjective disease burden of 
chemotherapy induced polyneuropathy; it also helped to verify the information retrieved from 
the medical records. A 100% response rate was achieved.  
 
Chemomobilization and autologous stem cell transplantation 
Gemcitabine was administered to all patients as a 30 minute infusion at 1250 mg/m2 on day 
1, and filgrastim (G-CSF) was given subcutaneously at a dose of 1 Mio U/kg/day divided into 
two daily doses. G-CSF was started on day 4 and continued until (and including) the day of 
stem cell collection. Apheresis was triggered at the first day with more than 15’000 CD34+ 
cells/ml in the peripheral blood. 2 x 106 CD34+ cells/kg was the minimum collection 
requirement, and we aimed to collect between 3-5 x 106 CD34+ cells/kg per transplant, with 
usually two transplants being planned. Cell processing procedures followed local standards. 
Patients received single-day high-dose chemotherapy with melphalan administered 
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intravenously at a dose of 200mg/m2, with peripheral stem cell transplantation at the 
following day.  
 
Definitions 
The two primary objectives of the study were safety and effectiveness of gemcitabine 
mobilization treatment. We studied CIPN during induction, mobilization, high-dose and 
maintenance treatment. We assessed incidence, severity, localization, and specific 
treatment. CIPN was defined as gemcitabine-induced, when patients presented novel or 
increased symptoms within two weeks after its administration. CIPN during bortezomib-
based induction treatment was identified when it occurred between the first bortezomib 
administration and up to 30 days after the last dose. CIPN was assessed according to the 
modified version of the National Cancer Institute Common Toxicity Criteria for Adverse 
Events (NCI-CTCAE; version 4.03). We used the following categories: general sensory 
neuropathy (paresthesia, dysesthesia, hypesthesia, hyperesthesia, hyporeflexia, hypalgesia, 
and decreased temperature sensation); neuropathic pain; general motoric neuropathy 
(muscle weakness); fasciculation (including tremor and spasm); and ataxia. We also 
investigated the need for specific analgetic CIPN medication as well as modification or 
interruption of myeloma specific treatment in order to control CIPN symptoms.  
 
Statistical analysis 
We applied descriptive statistics to calculate variables. We summarized the number of 
observations, median and range for continuous variables, and we calculated the number and 
percentage of patients in each category for categorical data. Nominal variables were 
compared with Fisher exact tests. We used non-parametric Mann-Whitney-U tests for 
continuous variables. The response rates were defined according to the IMWG criteria. OS 
was the time from transplantat until the date of death from any cause. PFS was the time from 
transplantat to first progression, relapse or death whichever occurred first. Patients without 
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progression or death were censored at their last follow-up. We designed time-to-event 
estimates (PFS, OS) according to the Kaplan-Meier method using the log-rank (Mantel-Cox) 
test. Data cut-off date was April 1, 2015. All p-values were two-sided, and a P-value of less 
than .05 was considered statistically significant. We performed all analyses using the 
GraphPadPrism software (Version 6.0b, GraphPad Software, Inc, San Diego, CA).  
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RESULTS 
 
Patients 
Between 03/2012 and 02/2013, 24 consecutive myeloma patients at the University Hospital 
in Bern, Switzerland received bortezomib/dexamethasone-based first-line induction treament 
and subsequent chemomobilization with gemcitabine and G-CSF as per protocol. The patient 
characteristics at diagnosis and additional information on the chemotherapy regimens are 
listed in Table 1. The median age at diagnosis of the patients in our cohort was 61 years 
(range 52-70 years). Patients mostly had IgG subtype (50%), whereas the type of light 
chains involved and ISS stages were equally distributed. FISH analyses was available in 17 
patients (71%). All 24 patients received an induction treatment with bortezomib and 
dexamethasone (VD). In addition, two patients further received cyclophosphamide (VCD), 
two patients had doxorubicin (PAD), two patients were also treated with thalidomide (VTD), 
and two patients received lenalidomide (VRD), respectively. 
 
Stem cell mobilization and transplantation 
Detailed information on mobilization, stem cell collection and transplantation are summarized 
in Table 2. All patients received gemcitabine at the planned dose of 1250mg/m2 at day 1. 
None of the patients experienced neutropenia < 0.5 G/L or thrombocytopenia < 50 G/L 
following gemcitabine treatment. No bleeding complications and no febrile episodes requiring 
antibiotic treatment occurred. Two patients developed edema and weight gain requiring 
diuretic treatment. Ten of the 24 patients were hospitalized during the stem cell mobilization 
process, with all hospitalizations related to the application of a central venous catheter line 
for stem cell harvest, with a median hospitalization duration of two days, ranging from two to 
four days. In 19 patients (79%), a single day of apheresis was sufficient to obtain the 
minimum number of > 2 x 106 CD34+cells/kg, whereas five patients (21%) needed two days 
of stem cell collection. Apheresis was initiated after a median of 8 days (range 8 to 10 days) 
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after mobilization with gemcitabine. The total median duration of apheresis was 285 minutes, 
with a range from 70 to 420 minutes. The median final collection of CD34+ cells was 9.51 x 
106 cells/kg, with a range from 4.95 to 19.2. We found that more than 10 x 106 CD34+ 
cells/kg b.w. were collected in 54% of the patients. Finally, none of the patients improved the 
remission status following gemcitabine treatment. 
All patients in this study underwent subsequent high-dose chemotherapy with 
200mg/m2 melphalan, with peripheral stem cell transplantation at the following day. The 
patients received a median of 3.4 x 106 CD34+ cells/kg (range 2.0 to 5.4). All patients had 
successful engraftment. The median time to recovery was 11 days (range 11 to 13 days) for 
neutrophils (ANC > 0.5 G/l), 13 days (range 9 to 21 days) for platelets > 20x109/l, and 20 
days (range 15 to 40 days) for platelets > 100x109/l. Maintenance treatment after ASCT was 
given in 15 patients (63%), with lenalidomide in all these patients. 
 
Chemotherapy induced polyneuropathy (CIPN) 
The incidence of CIPN during induction and mobilization treatment is summarized in Table 3. 
In one patient (5%), polyneuropathy was pre-existing, most likely due to diabetes mellitus in 
this patient. Evaluation of clinical assessment together with the patient questionnaire 
indicated that any signs of clinical manifestation of CIPN during bortezomib-based induction 
treatment occurred in 21 of 24 myeloma patients (88%). We found that the differences 
observed in the total incidence of CIPN as documented by the treating physicians in their 
medical charts compared to the data retrieved from individual questionnaires were not 
significant (P = .45).  
Symptoms of CIPN were first reported after a mean of 6.88 weeks of bortezomib 
treatment. As depicted in Table 4, CIPN affected patients predominantly reported sensory 
symptoms (68%), with grade I/II in 48% and grade III/IV in 20%. Motoric symptoms were 
documented in 7 patients (28%), all being grade I or II. Ataxia was identified in two patients 
(8%). Standard medication given for neuropathic pain involved pregabalin, gabapentin and 
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opioids. Finally, four patients (16%) of the patients needed bortezomib dose reduction, 
prolongation of treatment interval or even interruption of therapy as a consequence of the 
occurrence of bortezomib-induced CIPN. In two patients (8%), CIPN resulted in the 
premature discontinuation of bortezomib treatment. However, none of the patients in this 
study received a second line of chemotherapy, for whatever reason, before mobilization 
treatment. 
Noteworthy, we observed only one patient (4%) with worsening of bortezomib-
induced sensory CIPN (from grade I to II) during and following mobilization treatment with 
gemcitabine. Also, a single patient (4%) reported worsening of bortezomib-induced sensory 
CIPN (from grade I to II) following high-dose chemotherapy. During lenalidomide 
maintenance treatment, two patients (8%) had worsening of CIPN (one patient from grade I 
to II, and one patient from grade II to III) as summarized in Table 4. 
Repetitive follow-up information on the course of CIPN was available for all patients. 
Symptoms of CIPN resolved in 14% of all patients (n=3) until the day 100 assessment after 
HDCT. In additional 9 (41%) patients, symptoms gradually improved over time with a median 
time to disappearance of 5 months (range 4 to 9 months). However, 18% of the patients 
(n=4) only had a partial improvement of CIPN, and 27% of the patients (n=6) considered 
CIPN still present and a “major problem”. Patients described a “very high burden” due to 
CIPN in 23%, and a “high burden” in another 23%. For 45% of the patients, CIPN was 
“tolerable and modest”, whereas only 9% considered it “harmless” (data not shown). 
 
Outcome 
Information on outcome is limited by the small number of study patients. Consequently, we 
observed no significant differences in response rates at mobilization and 100 days after 
ASCT when comparing patients with and without CIPN before ASCT. Eight of all 24 study 
patients so far had a relapse after ASCT, with the median relapse-free survival being not yet 
reached after a median follow-up of 31 months. The relapse-free survival two years after 
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ASCT was 72%. Figure 1A depicts the relapse-free survival (RFS) of the entire study cohort, 
and Figure 1B indicates the overall survival (OS). Two patients died so far, after 10 and 13 
months, in both cases due to myeloma progression. Again, the median survival of the entire 
study cohort was not yet reached, and the median overall survival after two years was 92%.  
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DISCUSSION  
 
Bortezomib based regimens for first-line induction treatment have improved remission and 
survival rates in myeloma patients and have become standard of care (Richardson et al, 
2003; Sonneveld et al, 2013). However, chemotherapy-induced polyneuropathy (CIPN) is a 
major and often limiting side effect of bortezomib (Argyriou et al, 2008; Delforge et al, 2010; 
Keller et al, 2015; Koeppen et al, 2014; Mohty et al, 2010; Richardson et al, 2006). In our 
study cohort, 88% of myeloma patients treated with subcutaneous bortezomib developed 
clinical signs of neuropathy of any grade which led in 16% to prolongation of treatment 
intervals or discontinuation of bortezomib treatment. The majority of the patients had sensory 
deficits which is consistent with previous reports on bortezomib inducing a dose-related 
peripheral, mainly sensory polyneuropathy with accompanying neuropathic pain (Argyriou et 
al, 2008; Delforge et al, 2010; Keller et al, 2015; Koeppen et al, 2014; Mohty et al, 2010; 
Richardson et al, 2006). Thus, optimized concepts for the prevention and treatment of 
bortezomib induced CIPN are obviously essential for myeloma patients, and such strategies 
involve subcutaneous application, the once weekly administration, and timely discontinuation 
at early signs of neuropathy to enable reversibility of symtoms (Argyriou et al, 2008; Cavaletti 
et al, 2010; Stubblefield et al, 2009). 
Bortezomib associated CIPN is significantly affecting the quality of life of myeloma 
patients. The majority (63%) of myeloma patients affected by CIPN in our study considered 
the burden of CIPN as “high” or “very high”, and more than half of the patients with CIPN 
failed to completely recover from CIPN, with 31% reporting unchanged persisting CIPN after 
completion of HDCT treatment. 
Based on these considerations, we evaluated an alternative chemomobilization 
approach after bortezomib induction. Traditionally, the standard strategy in Switzerland to 
mobilize peripheral autologous stem cells in myeloma patients is a single-dose of 35 mg/m2 
vinorelbine, with G-CSF stimulation initiated four days later (Bargetzi et al, 2003; Heizmann 
et al, 2009; Samaras et al, 2015; Schmid et al, 2015). This non-myelosuppressive concept 
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allows a highly reliable and efficient stem cell collection at day 8. This concept has been 
challenged in the last years with the predominant use of bortezomib during induction 
treatment and with bortezomib induced polyneuropathy (CIPN) as its major side effect. The 
vinca-alkaloid vinorelbine is mediating additional neurotoxicity (Capasso et al, 2012; Galano 
et al, 2011; Lobert et al, 1996), involving hypoesthesia, hyporeflexia, paresthesia and pain, 
but also motoric or autonomic axons can be dammaged, which is similar to the neurotoxic 
profile of bortezomib (Capasso et al, 2012; Galano et al, 2011; Lobert et al, 1996). In fact, we 
previously reported that a single dose of vinorelbine can significantly aggravate bortezomib 
induced CIPN - or induce first manifestation of CIPN - in bortezomib pretreated myeloma 
patients (Keller et al, 2015). These observations formed the basis of our study to evaluate an 
alternative chemomobilization approach while preserving the advantages of a non-
myelosuppressive strategy. 
Gemcitabine is a promising candidate for chemomobilization. It has been studied so 
far as a component of a polychemotherapy mobilization strategy in relapsed Hodgkin 
lymphoma patients and has been considered both safe and effective (Suyani et al, 2011). 
However, it has not been used so far as monochemotherapy for mobilization of autologous 
stem cells. We found that a single dose of 1250mg/m2 gemcitabine – together with G-CSF 
stimulation started at day 4 after gemcitabine – was effective to allow the collection of 
autologous stem cells in all 24 study patients. Consequently, all patients proceeded to 
subsequent high-dose chemotherapy treatment and enjoyed timely hematologic recovery 
and no unexpected infectious or toxic complications. Importantly, we did not observe 
significant aggravation of bortezomib-induced CIPN - or first occurrence of CIPN - in 
bortezomib-pretreated myeloma patients following the administration of gemcitabine. These 
observations suggest that gemcitabine can safely replace vinorelbine for chemomobilization 
of autologous stem cells in bortezomib-pretreated myeloma patients. 
High-dose cyclophosphamide chemotherapy with G-CSF represents the most 
commonly used chemomobilization regimen. Our data suggest that the combination of G-
CSF with a single dose of non-myelosuppressive chemotherapy with gemcitabine compares 
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favorably to cyclophosphamide mobilization because of its reliable and predictable collection 
rate at day 8, the strictly ambulatory setting, and the lack of febrile complications notoriously 
associated with cyclophosphamide mobilization. 
We undertook considerable efforts to identify CIPN during induction and mobilization 
chemotherapy, but also during high-dose chemotherapy and lenalidomide maintenance 
treatment. All patients were clinically monitored for the development and assessment of the 
severity of CIPN, and patients also reported their observations using a standardized 
questionnaire. The finding of 88% of all patients showing signs of CIPN after bortezomib 
induction treatment in this small study appears high compared to other larger series, Thus, a 
by chance effect due to the small sample size may have contributed to this high incidence. 
However, our study points to the possibility that CIPN may remain unrecognized by both 
treating physicians and patients unaware of the variety of CIPN symptoms. 
We observed one patient with aggravation of bortezomib-induced CIPN (from grade I 
to II) after gemcitabine, one patient after high-dose melphalan chemotherapy, and two 
patients under lenalidomide maintenance treatment. These observations underline the 
concept that gemcitabine mobilization, high-dose melphalan and lenalidomide maintenance 
are not neurotoxic myeloma treatments, and the rare observation of novel neuropathy in 
bortezomib-pretreated patients suggests the possibility of other mechanisms. Recently, late 
onset of previously not overt bortezomib induced polyneuropathy was observed, emerging 
mainly during or shortly after peripheral blood stem cell (PBSC) collection (Tacchetti et al, 
2014). A coasting phenomenon of bortezomib was suggested rather than an effect of 
compounds used between bortezomib-based induction treatment and PBSC collection 
(Tacchetti et al, 2014). Possibly, such late occurrence of bortezomib toxicity may have been 
involved in the few patients with CIPN occurring after discontinuation of beortezomib 
treatment. 
We identified a slow recovery rate from bortezomib triggered polyneuropathy. In fact, 
half of all affected patients continued to suffer from symptoms of disabling CIPN after 
completion of HDCT treatment. Previous reports suggested that bortezomib (or vinorelbine-) 
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induced neuropathy was predominantly reversible after drug discontinuation within two to 
four months (Argyriou et al, 2008; Koeppen et al, 2014; Mohty et al, 2010). In contrast, 
improvement of CIPN in our cohort remained incomplete in a significant proportion of 
patients. In the absence of effective treatment modalities for CIPN, prevention of severe 
CIPN remains an important goal of induction treatment in myeloma patients (Cavaletti et al, 
2010; Mantyh et al, 2006; Stubblefield et al, 2009). 
This study was not powered to evaluate the effect of the development of CIPN on 
response and survival rates. In fact, we observed no differences in response and survival 
rates between myeloma patients with and without CIPN. However, developing CIPN can 
affect dosing, duration and the chemotherapy composition of later myeloma treatment 
thereby affecting response to treatment (Cavaletti et al, 2010; Mantyh et al, 2006; 
Stubblefield et al, 2009). Consequently, longer follow-up of a larger cohort may be required 
to ultimately provide answers to these issues. However, our data suggest that gemcitabine 
represents a promising alternative candidate to replace neurotoxic vinorelbine 
chemomobilization. Consequently, we initiated a randomized prospective trial comparing 
vinorelbine and gemcitabine mobilization chemotherapy in myeloma patients, and this trial 
may ultimately identify a novel role for gemcitabine as a non-neurotoxic and effective stem 
cell mobilization regimen in myeloma patients.  
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TITLES AND LEGENDS TO FIGURES  
 
Figure 1: A) Kaplan-Meier curves are depicted for the relapse-free survival (RFS) and B) for 
the overall survival (OS) of the entire study cohort. 
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  Table 1 - Patient characteristics 
  
 
    
  
  
 n = 24 
  age at diagnosis; median (y
a
, range) 61 (52-70) 
  sex, m/f; n (%) 13/11 (54/46) 
  IgG n (%) 12 (50) 
  IgA n (%) 7 (29) 
  IgD  n (%) 1 (4) 
  light-chain only 3 (13) 
  asecretory 1 (4) 
  kappa 12 (50) 
  lambda 12 (50) 
  stage Durie & Salmon I 8 (33) 
  
 
                                II 7 (29) 
  
 
                                III 9 (38) 
  
 
                                A 17 (71) 
  
 
                                B 7 (29) 
  Stage ISS I 8 (33) 
  
 
             II 7 (29) 
                 III 9 (38) 
  FISH/cytogenetics
b
: not done            7 (29) 
 
                                 trisomies 12 (50) 
                                 tetrasomy 9 1 (4) 
                                 deletion 1q 2 (8) 
                                 deletion 13q 6 (24) 
                                 deletion 17p 5 (20) 
                                 monosomy 4 1 (4) 
                                 monosomy 14 1 (4) 
                                 t(4;14) 2 (8) 
                                 t(14;18) 1 (4) 
                                 t(14;16) 3 (13) 
  Induction treatment 
   bortezomib/dexamethason-based (VD)                24 (100)  
  
 
 + cyclophosphamide (VCD)   16 (68) 
  
 
 + anthracyclin (PAD)      2 (8) 
  
 
 + thalidomide (VTD)      2 (8) 
  
 
 + lenalidomide (RVD)      2 (8) 
  
 
VD      2 (8) 
  cycles, median (mean) 4 (3.67) 
     range 2 - 6 
  second induction regimen 0 (0) 
  maintenance treatment: none   9 (37) 
            with lenalidomide  15 (63) 
            duration months, median (mean) 12 (14) 
 
          range   2-24 
___________________________________ 
 
a
y: years; 
b
7 patients had multiple findings. 
 
Page 23 of 48
URL: http://mc.manuscriptcentral.com/glal
Leukemia and Lymphoma
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 
  Table 2: Mobilization and transplantation. 
  
    
  
gemcitabine chemotherapy  + G-
CSF, n (%) 
24 (100) 
  one day of apheresis 19 (79) 
  two days of apheresis 5 (21) 
  1st apheresis at day 8 16 (67) 
  1st apheresis at day 9 7 (29) 
  1st apheresis at day 10 1 (4) 
     median (mean) 8 (8.38 ± 0.57) 
  duration of apheresis, mean, minutes 269.71 ± 91.27 
     median, minutes (range) 285 (70 - 420) 
 mean blood volume processed, liters 26.2 
    median, liters (range) 25.3 (13.5 – 33.9) 
  leukocytes at apheresis 
a
, mean (G/l) 33.80 ± 12.94 
     median (range) 34.4 (7.90 - 55.6) 
  peripheral CD34-Wert at apheresis 
a
 
 
     mean (x 10
 9
 / ml PB) 56.3 ± 38.1 
     median, x 10 6 / ml PB (range) 50.5 (4.4-122.4) 
  % CD34 leukocytes at apheresis 
a
  
 
     mean 0.19 ± 0.32 
     median (range) 0.14 (0.02 - 0.68) 
  total collected CD34+ x 10
6
 / kg b.w.
d
 
 
     mean 10.09 ± 6.61 
     median (range) 9.51 (4.95 - 19.2) 
 patients with > 5 x 10
6
 / kg CD34+ 23 (96) 
    cells after the 1
st
 day of apheresis  
  transfused CD34+ x 10
6
 / kg b.w.
d
   
     mean 3.51 ± 0.97 
     median (range) 3.4 (2.0 - 5.4) 
  first day of ANC
b
 > 0,5x109/L - n (%) 
 
     day 11 14 (58) 
     day 12 9 (38) 
     day 13 1 (4) 
     mean 11.46 ± 0.58 
     median (range) 11 (11 - 13) 
  first day of Plts
c
 > 20x109/L - n (%) 
 
     days 10-12 5 (21) 
     day 13 8 (33) 
     days 14-15 9 (38) 
     >day 15 2 (8) 
     mean 13.63 ± 2.27 
     median (range) 13 (9 - 21) 
  first day of Plts
c
 > 100x109/L - n (%) 
 
     ≤ day 20                   13 (54) 
     days 20-30 8 (33) 
     >day 30 3 (12) 
     mean 22.04 ± 5.88 
     median (range) 20 (15 - 40) 
___________________________________________________________________ 
 
a 
at the first day of apheresis; 
b 
ANC: absolute neutrophil count; 
c 
Plts; platelets; in the absence for transfusions in the previous 
three days; 
d 
b.w.: body weight. 
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  Table 3: Outcome     
  
    
 
Remission status at transplantation 
  
    stable disease            1 (4)  
     partial remission 10 (42) 
     very good partial remission 12 (50) 
     complete remission 1 (4) 
  100 days after transplant 
 
     complete remission 13 (54) 
     not in complete remission 11 (46) 
  Relapse, n (%)  8 (33) 
  Death due to progression, n (%) 
a
            2 (8) 
 
Follow-up, mean, months 26 ± 4.82 
     median (range) 31 (26-36) 
________________________________ 
 
a 
Two patients died, both due to myeloma progression. 
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  Table 4: Peripheral neuropathy (PN ). 
     
   
 
preexisting PN at first diagnosis
 c
 1 (4) 
 
first occurrence during induction 21 (88) 
 
   duration until occurrence, weeks, mean 6.88 ± 3.04 
 
 first occurrence at mobilization 0 (0) 
 
   worsening of PN at mobilization 1 (4) 
 
first occurrence at high-dose treatment 0 (0) 
 
   worsening of PN at high-dose treatment 1 (4) 
 
first occurrence during maintenance 0 (0) 
     worsening of PN during maintenance 2 (8) 
  
   
  sensory PN
 b, d
 15 (68) 
  
 
I / II 
 
                10 (48) 
  
 
III / IV 
 
                  5 (20) 
  motory PN
 b, d
 7 (28) 
  
 
I /II 
 
                 7 (28) 
  
 
III / IV 
 
                   0 (0) 
  Ataxia 
b, d
  2 (8) 
  
 
I / II 
 
                   2 (8) 
  
 
III 
 
                   0 (0) 
  
   
  PN disappeared at day 100 
a
 3 (14) 
  PN disappeared later 9 (41) 
        mean, months 5.56 ± 1.34 
        median (range), months 5 (4 - 9) 
  PN improved, but still present 4 (18) 
  PN present and still a major problem 6 (27) 
  
    
  Subjective burden of disease:  high 5 (23) 
                                                    rather high 5 (23) 
                                                    modest 10 (45) 
                                                    harmless 2 (9) 
___________________________________________________________________ 
a 
At 100 days after high-dose chemotherapy; 
b
 three patients had more than one quality of PN; 
c 
PN: polyneuropathy; 
d 
maximum 
degree observed. 
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Stem cell mobilization chemotherapy with gemcitabine is effective and 
safe in myeloma patients with bortezomib induced neurotoxicity. 
 
 
AUTHORS: 1Beatrice U. Mueller, 2Sandra Keller, 1Katja Seipel, 3Behrouz Mansouri 
Taleghani, 4Daniel Rauch, 5Daniel Betticher, 6Thomas Egger,  2Thomas Pabst. 
 
 
AFFILIATIONS: 1Department of Clinical Research, University of Berne; Berne, Switzerland; 
2Department of Medical Oncology, University Hospital of Berne; Berne, Switzerland; 
3Department of Hematology, University Hospital of Berne; Berne, Switzerland; 4Department 
of Oncology; Kantonsspital; Thun, Switzerland; 5Department of Oncology; Kantonsspital; 
Fribourg, Switzerland; and 6Department of Oncology; Kantonsspital; Solothurn, Switzerland. 
 
 
RUNNING HEAD: Gemcitabine for mobilization in myeloma. 
 
 
ABBREVIATIONS: MM: multiple myeloma; HDCT: high-dose chemotherapy; ASCT: 
autologous stem cell transplantation; G-CSF: granulocyte-colony stimulating factor; PN: 
peripheral neuropathy; CIPN: chemotherapy-induced peripheral neuropathy; BIPN: 
bortezomib-induced peripheral neuropathy; OS: overall survival; PFS: progression-free 
survival. 
 
 
MANUSCRIPT DETAILS: abstract: 199 words (200 allowed); manuscript word count: 2832 
words (3’000 allowed); 4 tables; 1 figure; no supplemental material; 27 references. 
 
 
CORRESPONDING AUTHOR: Thomas Pabst MD; Associate Professor; Department of 
Medical Oncology; University Hospital; Berne; Switzerland. Phone: ++41 31 632 8430; fax: 
++41 31 632 3410; Email: thomas.pabst@insel.ch. 
 
Page 27 of 48
URL: http://mc.manuscriptcentral.com/glal
Leukemia and Lymphoma
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
2 
 
Mueller et al                                                                                               Gemcitabine for mobilization in myeloma. 
SUMMARY  
 
Background: Vinorelbine chemotherapy with G-CSF stimulation is a widely applied non-
myelosuppressive mobilization regimen in Switzerland for myeloma patients, but its 
neurotoxic potential limits its use in patients with bortezomib induced polyneuropathy.  
Methods: In this single-center study, we alternatively evaluated safety and effectiveness of 
gemcitabine chemotherapy with G-CSF for mobilization of autologous stem cells.  
Results: Between 03/2012 and 02/2013, all bortezomib pretreated myeloma patients planned 
to undergo first-line high-dose melphalan chemotherapy received a single dose of 
1250mg/m2 gemcitabine, with G-CSF started on day four. The 24 patients in this study have 
received a median of four cycles of bortezomib-dexamethason based induction. Bortezomib-
caused polyneuropathy was identified in 21 patients (88%) by clinical evaluation and a 
standardized questionnaire. Administration of gemcitabine mobilization did not induce novel 
or aggravate preexisting neuropathy. Stem cell mobilization was successful in all 24 patients, 
with a single day of apheresis being sufficient in 19 patients (78%). The median yield was 
9.51 x 106 CD34+ cells/kg. Stem collection could be accomplished at day 8 in 67%.  
Conclusion: Our data suggest that single-dose gemcitabine together with G-CSF is an 
effective mobilization regimen in myeloma patients and a safe alternative non-
myelosuppressive mobilization chemotherapy for myeloma patients with bortezomib induced 
polyneuropathy.  
 
 
 
KEY WORDS: mobilization; stem cells; myeloma; polyneuropathy; gemcitabine; bortezomib; 
neurotoxicity; autologous; transplant. 
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INTRODUCTION 
 
Significant advances have been reported in the treatment of myeloma patients in the last 
decades. The introduction of proteasome inhibitors and immunomodulatory compounds for 
induction treatment, high-dose chemotherapy (HDCT) followed by autologous stem cell 
transplantation (ASCT) for consolidation, and subsequent maintenance treatment with 
lenalidomide or bortezomib have increased remission and survival rates in myeloma patients 
(Bladé et al, 2005; Fernand et al, 2005; Giralt et al, 2011; Harrousseau et al, 2009; Ludwig et 
al, 2010; Rajkumar, 2011). Noteworthy, a number of studies identified an independent benefit 
of first-line HDCT with ASCT also in the era of novel agents, which was further enhanced by 
maintenance treatment after HDCT (Bladé et al, 2005; Fernand et al, 2005; Giralt et al, 2011; 
Harrousseau et al, 2009). These observations indicate that ASCT continues to be a 
component of the first-line treatment algorithm for young and fit myeloma patients 
(Harrousseau et al, 2009; Ludwig et al, 2010). 
The optimal strategy to mobilize autologous stem cells from the bone marrow to the 
peripheral blood remains an issue of ongoing controversy (Giralt et al, 2011). Repetitive 
applications of the granulocyte colony-stimulating factor (G-CSF) alone can effectively 
mobilize peripheral CD34+ cells, whereas the combination of G-CSF with chemotherapy is 
usually associated with a more potent recruitment of CD34+ cells from the bone marrow 
niche. The additional administration of the expensive stem cell mobilizing compound 
plerixafor represents a rescue strategy for patients failing such mobilization strategies.  
Based on the considerations above, the combined use of chemotherapy and G-CSF 
is a widely used concept. While high-dose cyclophosphamide with G-CSF is commonly given 
for chemotherapy mobilization, the administration of a single dose of non-myelosuppressive 
chemotherapy with vinorelbine (35mg/m2) together with G-CSF started on day 4 is the 
standard mobilization regimen in Switzerland since more than a decade (Bargetzi et al, 2003; 
Heizmann et al, 2009; Samaras et al, 2015; Schmid et al, 2015). Its obvious advantages 
compared to cyclophosphamide treatment comprise a highly predictable stem cell collection 
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at day 8, the entirely ambulatory concept, and the lack of infectious and toxic complications 
notoriously following cyclophosphamide mobilization (Bargetzi et al, 2003; Heizmann et al, 
2009; Samaras et al, 2015; Schmid et al, 2015). 
With the predominant use of bortezomib during induction treatment and with 
chemotherapy-induced polyneuropathy (CIPN) as its major and often limiting side effect, the 
subsequent use of vinorelbine for mobilization has become increasingly problematic because 
of its added neurotoxicity (Argyriou et al, 2008; Carlson et al, 2011; Delforge et al, 2010; 
Keller et al, 2015; Koeppen et al, 2014; Mohty et al, 2010; Richardson et al, 2006; Swain et 
al, 2008). Clinically significant induction of novel - as well as aggravation of bortezomib 
induced - CIPN following mobilization treatment with a single dose of vinorelbine in myeloma 
patients has recently been reported by our group (Keller et al, 2015). These facts identified a 
need for an alternative non-neurotoxic mobilization chemotherapy, while preserving the 
advantages of a non-myelosuppressive strategy.  
Gemcitabine has been previously used for stem cell mobilization as a part of 
polychemotherapy regimens in Hodgkin lymphoma patients (Suyani et al, 2011). However, 
its use as monochemotherapy for mobilization has not been reported so far. In this study, we 
investigated the safety and effectiveness of gemcitabine together with G-CSF for the 
mobilization of autologous stem cells in myeloma patients after bortezomib/dexamethasone-
based induction treatment. 
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PATIENTS AND METHODS 
 
Patients and study design 
This is a single-center prospective study analyzing all consecutive myeloma patients 
undergoing first-line consolidation treatment with high-dose melphalan chemotherapy 
(HDCT) and autologous stem cell transplantation (ASCT) between 03/2012 and 02/2013. 
Patients must have been treated with a bortezomib/dexamethasone-based induction 
regimen, the age neded to be below 71 years, and a minimum renal function with a kreatinin 
clearance of 40ml/min and neutrophils above 1.0 G/L were required. Clinical characteristics 
and treatment details of the patient cohort are depicted in Table 1. The local ethics 
committee of Berne, Switzerland with decision #143/2014 approved this study.  
Data sources were medical records of the patients. Neuropathy was assessed by two 
independent investigators, with T.P. having been one of them for all study patients. In 
addition, a standardized questionnaire was filled out by all study patients. The questionnaire 
assessed signs and treatment of neuropathy as well as the subjective disease burden of 
chemotherapy induced polyneuropathy; it also helped to verify the information retrieved from 
the medical records. A 100% response rate was achieved.  
 
Chemomobilization and autologous stem cell transplantation 
Gemcitabine was administered to all patients as a 30 minute infusion at 1250 mg/m2 on day 
1, and filgrastim (G-CSF) was given subcutaneously at a dose of 1 Mio U/kg/day divided into 
two daily doses. G-CSF was started on day 4 and continued until (and including) the day of 
stem cell collection. Apheresis was triggered at the first day with more than 15’000 CD34+ 
cells/ml in the peripheral blood. 2 x 106 CD34+ cells/kg was the minimum collection 
requirement, and we aimed to collect between 3-5 x 106 CD34+ cells/kg per transplant, with 
usually two transplants being planned. Cell processing procedures followed local standards. 
Patients received single-day high-dose chemotherapy with melphalan administered 
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intravenously at a dose of 200mg/m2, with peripheral stem cell transplantation at the 
following day.  
 
Definitions 
The two primary objectives of the study were safety and effectiveness of gemcitabine 
mobilization treatment. We studied CIPN during induction, mobilization, high-dose and 
maintenance treatment. We assessed incidence, severity, localization, and specific 
treatment. CIPN was defined as gemcitabine-induced, when patients presented novel or 
increased symptoms within two weeks after its administration. CIPN during bortezomib-
based induction treatment was identified when it occurred between the first bortezomib 
administration and up to 30 days after the last dose. CIPN was assessed according to the 
modified version of the National Cancer Institute Common Toxicity Criteria for Adverse 
Events (NCI-CTCAE; version 4.03). We used the following categories: general sensory 
neuropathy (paresthesia, dysesthesia, hypesthesia, hyperesthesia, hyporeflexia, hypalgesia, 
and decreased temperature sensation); neuropathic pain; general motoric neuropathy 
(muscle weakness); fasciculation (including tremor and spasm); and ataxia. We also 
investigated the need for specific analgetic CIPN medication as well as modification or 
interruption of myeloma specific treatment in order to control CIPN symptoms.  
 
Statistical analysis 
We applied descriptive statistics to calculate variables. We summarized the number of 
observations, median and range for continuous variables, and we calculated the number and 
percentage of patients in each category for categorical data. Nominal variables were 
compared with Fisher exact tests. We used non-parametric Mann-Whitney-U tests for 
continuous variables. The response rates were defined according to the IMWG criteria. OS 
was the time from transplantat until the date of death from any cause. PFS was the time from 
transplantat to first progression, relapse or death whichever occurred first. Patients without 
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progression or death were censored at their last follow-up. We designed time-to-event 
estimates (PFS, OS) according to the Kaplan-Meier method using the log-rank (Mantel-Cox) 
test. Data cut-off date was April 1, 2015. All p-values were two-sided, and a P-value of less 
than .05 was considered statistically significant. We performed all analyses using the 
GraphPadPrism software (Version 6.0b, GraphPad Software, Inc, San Diego, CA).  
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RESULTS 
 
Patients 
Between 03/2012 and 02/2013, 24 consecutive myeloma patients at the University Hospital 
in Bern, Switzerland received bortezomib/dexamethasone-based first-line induction treament 
and subsequent chemomobilization with gemcitabine and G-CSF as per protocol. The patient 
characteristics at diagnosis and additional information on the chemotherapy regimens are 
listed in Table 1. The median age at diagnosis of the patients in our cohort was 61 years 
(range 52-70 years). Patients mostly had IgG subtype (50%), whereas the type of light 
chains involved and ISS stages were equally distributed. FISH analyses was available in 17 
patients (71%). All 24 patients received an induction treatment with bortezomib and 
dexamethasone (VD). In addition, two patients further received cyclophosphamide (VCD), 
two patients had doxorubicin (PAD), two patients were also treated with thalidomide (VTD), 
and two patients received lenalidomide (VRD), respectively. 
 
Stem cell mobilization and transplantation 
Detailed information on mobilization, stem cell collection and transplantation are summarized 
in Table 2. All patients received gemcitabine at the planned dose of 1250mg/m2 at day 1. 
None of the patients experienced neutropenia < 0.5 G/L or thrombocytopenia < 50 G/L 
following gemcitabine treatment. No bleeding complications and no febrile episodes requiring 
antibiotic treatment occurred. Two patients developed edema and weight gain requiring 
diuretic treatment. Ten of the 24 patients were hospitalized during the stem cell mobilization 
process, with all hospitalizations related to the application of a central venous catheter line 
for stem cell harvest, with a median hospitalization duration of two days, ranging from two to 
four days. In 19 patients (79%), a single day of apheresis was sufficient to obtain the 
minimum number of > 2 x 106 CD34+cells/kg, whereas five patients (21%) needed two days 
of stem cell collection. Apheresis was initiated after a median of 8 days (range 8 to 10 days) 
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after mobilization with gemcitabine. The total median duration of apheresis was 285 minutes, 
with a range from 70 to 420 minutes. The median final collection of CD34+ cells was 9.51 x 
106 cells/kg, with a range from 4.95 to 19.2. We found that more than 10 x 106 CD34+ 
cells/kg b.w. were collected in 54% of the patients. Finally, none of the patients improved the 
remission status following gemcitabine treatment. 
All patients in this study underwent subsequent high-dose chemotherapy with 
200mg/m2 melphalan, with peripheral stem cell transplantation at the following day. The 
patients received a median of 3.4 x 106 CD34+ cells/kg (range 2.0 to 5.4). All patients had 
successful engraftment. The median time to recovery was 11 days (range 11 to 13 days) for 
neutrophils (ANC > 0.5 G/l), 13 days (range 9 to 21 days) for platelets > 20x109/l, and 20 
days (range 15 to 40 days) for platelets > 100x109/l. Maintenance treatment after ASCT was 
given in 15 patients (63%), with lenalidomide in all these patients. 
 
Chemotherapy induced polyneuropathy (CIPN) 
The incidence of CIPN during induction and mobilization treatment is summarized in Table 3. 
In one patient (5%), polyneuropathy was pre-existing, most likely due to diabetes mellitus in 
this patient. Evaluation of clinical assessment together with the patient questionnaire 
indicated that any signs of clinical manifestation of CIPN during bortezomib-based induction 
treatment occurred in 21 of 24 myeloma patients (88%). We found that the differences 
observed in the total incidence of CIPN as documented by the treating physicians in their 
medical charts compared to the data retrieved from individual questionnaires were not 
significant (P = .45).  
Symptoms of CIPN were first reported after a mean of 6.88 weeks of bortezomib 
treatment. As depicted in Table 4, CIPN affected patients predominantly reported sensory 
symptoms (68%), with grade I/II in 48% and grade III/IV in 20%. Motoric symptoms were 
documented in 7 patients (28%), all being grade I or II. Ataxia was identified in two patients 
(8%). Standard medication given for neuropathic pain involved pregabalin, gabapentin and 
Page 35 of 48
URL: http://mc.manuscriptcentral.com/glal
Leukemia and Lymphoma
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
10 
 
Mueller et al                                                                                               Gemcitabine for mobilization in myeloma. 
opioids. Finally, four patients (16%) of the patients needed bortezomib dose reduction, 
prolongation of treatment interval or even interruption of therapy as a consequence of the 
occurrence of bortezomib-induced CIPN. In two patients (8%), CIPN resulted in the 
premature discontinuation of bortezomib treatment. However, none of the patients in this 
study received a second line of chemotherapy, for whatever reason, before mobilization 
treatment. 
Noteworthy, we observed only one patient (4%) with worsening of bortezomib-
induced sensory CIPN (from grade I to II) during and following mobilization treatment with 
gemcitabine. Also, a single patient (4%) reported worsening of bortezomib-induced sensory 
CIPN (from grade I to II) following high-dose chemotherapy. During lenalidomide 
maintenance treatment, two patients (8%) had worsening of CIPN (one patient from grade I 
to II, and one patient from grade II to III) as summarized in Table 4. 
Repetitive follow-up information on the course of CIPN was available for all patients. 
Symptoms of CIPN resolved in 14% of all patients (n=3) until the day 100 assessment after 
HDCT. In additional 9 (41%) patients, symptoms gradually improved over time with a median 
time to disappearance of 5 months (range 4 to 9 months). However, 18% of the patients 
(n=4) only had a partial improvement of CIPN, and 27% of the patients (n=6) considered 
CIPN still present and a “major problem”. Patients described a “very high burden” due to 
CIPN in 23%, and a “high burden” in another 23%. For 45% of the patients, CIPN was 
“tolerable and modest”, whereas only 9% considered it “harmless” (data not shown). 
 
Outcome 
Information on outcome is limited by the small number of study patients. Consequently, we 
observed no significant differences in response rates at mobilization and 100 days after 
ASCT when comparing patients with and without CIPN before ASCT. Eight of all 24 study 
patients so far had a relapse after ASCT, with the median relapse-free survival being not yet 
reached after a median follow-up of 31 months. The relapse-free survival two years after 
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ASCT was 72%. Figure 1A depicts the relapse-free survival (RFS) of the entire study cohort, 
and Figure 1B indicates the overall survival (OS). Two patients died so far, after 10 and 13 
months, in both cases due to myeloma progression. Again, the median survival of the entire 
study cohort was not yet reached, and the median overall survival after two years was 92%.  
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DISCUSSION  
 
Bortezomib based regimens for first-line induction treatment have improved remission and 
survival rates in myeloma patients and have become standard of care (Richardson et al, 
2003; Sonneveld et al, 2013). However, chemotherapy-induced polyneuropathy (CIPN) is a 
major and often limiting side effect of bortezomib (Argyriou et al, 2008; Delforge et al, 2010; 
Keller et al, 2015; Koeppen et al, 2014; Mohty et al, 2010; Richardson et al, 2006). In our 
study cohort, 88% of myeloma patients treated with subcutaneous bortezomib developed 
clinical signs of neuropathy of any grade which led in 16% to prolongation of treatment 
intervals or discontinuation of bortezomib treatment. The majority of the patients had sensory 
deficits which is consistent with previous reports on bortezomib inducing a dose-related 
peripheral, mainly sensory polyneuropathy with accompanying neuropathic pain (Argyriou et 
al, 2008; Delforge et al, 2010; Keller et al, 2015; Koeppen et al, 2014; Mohty et al, 2010; 
Richardson et al, 2006). Thus, optimized concepts for the prevention and treatment of 
bortezomib induced CIPN are obviously essential for myeloma patients, and such strategies 
involve subcutaneous application, the once weekly administration, and timely discontinuation 
at early signs of neuropathy to enable reversibility of symtoms (Argyriou et al, 2008; Cavaletti 
et al, 2010; Stubblefield et al, 2009). 
Bortezomib associated CIPN is significantly affecting the quality of life of myeloma 
patients. The majority (63%) of myeloma patients affected by CIPN in our study considered 
the burden of CIPN as “high” or “very high”, and more than half of the patients with CIPN 
failed to completely recover from CIPN, with 31% reporting unchanged persisting CIPN after 
completion of HDCT treatment. 
Based on these considerations, we evaluated an alternative chemomobilization 
approach after bortezomib induction. Traditionally, the standard strategy in Switzerland to 
mobilize peripheral autologous stem cells in myeloma patients is a single-dose of 35 mg/m2 
vinorelbine, with G-CSF stimulation initiated four days later (Bargetzi et al, 2003; Heizmann 
et al, 2009; Samaras et al, 2015; Schmid et al, 2015). This non-myelosuppressive concept 
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allows a highly reliable and efficient stem cell collection at day 8. This concept has been 
challenged in the last years with the predominant use of bortezomib during induction 
treatment and with bortezomib induced polyneuropathy (CIPN) as its major side effect. The 
vinca-alkaloid vinorelbine is mediating additional neurotoxicity (Capasso et al, 2012; Galano 
et al, 2011; Lobert et al, 1996), involving hypoesthesia, hyporeflexia, paresthesia and pain, 
but also motoric or autonomic axons can be dammaged, which is similar to the neurotoxic 
profile of bortezomib (Capasso et al, 2012; Galano et al, 2011; Lobert et al, 1996). In fact, we 
previously reported that a single dose of vinorelbine can significantly aggravate bortezomib 
induced CIPN - or induce first manifestation of CIPN - in bortezomib pretreated myeloma 
patients (Keller et al, 2015). These observations formed the basis of our study to evaluate an 
alternative chemomobilization approach while preserving the advantages of a non-
myelosuppressive strategy. 
Gemcitabine is a promising candidate for chemomobilization. It has been studied so 
far as a component of a polychemotherapy mobilization strategy in relapsed Hodgkin 
lymphoma patients and has been considered both safe and effective (Suyani et al, 2011). 
However, it has not been used so far as monochemotherapy for mobilization of autologous 
stem cells. We found that a single dose of 1250mg/m2 gemcitabine – together with G-CSF 
stimulation started at day 4 after gemcitabine – was effective to allow the collection of 
autologous stem cells in all 24 study patients. Consequently, all patients proceeded to 
subsequent high-dose chemotherapy treatment and enjoyed timely hematologic recovery 
and no unexpected infectious or toxic complications. Importantly, we did not observe 
significant aggravation of bortezomib-induced CIPN - or first occurrence of CIPN - in 
bortezomib-pretreated myeloma patients following the administration of gemcitabine. These 
observations suggest that gemcitabine can safely replace vinorelbine for chemomobilization 
of autologous stem cells in bortezomib-pretreated myeloma patients. 
High-dose cyclophosphamide chemotherapy with G-CSF represents the most 
commonly used chemomobilization regimen. Our data suggest that the combination of G-
CSF with a single dose of non-myelosuppressive chemotherapy with gemcitabine compares 
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favorably to cyclophosphamide mobilization because of its reliable and predictable collection 
rate at day 8, the strictly ambulatory setting, and the lack of febrile complications notoriously 
associated with cyclophosphamide mobilization. 
We undertook considerable efforts to identify CIPN during induction and mobilization 
chemotherapy, but also during high-dose chemotherapy and lenalidomide maintenance 
treatment. All patients were clinically monitored for the development and assessment of the 
severity of CIPN, and patients also reported their observations using a standardized 
questionnaire. The finding of 88% of all patients showing signs of CIPN after bortezomib 
induction treatment in this small study appears very high compared to other larger series, 
Thus, a by chance effect due to the small sample size may have contributed to this high 
incidence. However, our study points to the possibility that CIPN may remain unrecognized 
by both treating physicians and patients unaware of the variety of CIPN symptoms. 
We observed one patient with aggravation of bortezomib-induced CIPN (from grade I 
to II) after gemcitabine, one patient after high-dose melphalan chemotherapy, and two 
patients under lenalidomide maintenance treatment. These observations underline the 
concept that gemcitabine mobilization, high-dose melphalan and lenalidomide maintenance 
are not neurotoxic myeloma treatments, and the rare observation of novel neuropathy in 
bortezomib-pretreated patients suggests the possibility of other mechanisms. Recently, late 
onset of previously not overt bortezomib induced polyneuropathy was observed, emerging 
mainly during or shortly after peripheral blood stem cell (PBSC) collection (Tacchetti et al, 
2014). A coasting phenomenon of bortezomib was suggested rather than an effect of 
compounds used between bortezomib-based induction treatment and PBSC collection 
(Tacchetti et al, 2014). Possibly, such late occurrence of bortezomib toxicity may have been 
involved in the few patients with CIPN occurring after discontinuation of beortezomib 
treatment. 
We identified a slow recovery rate from bortezomib triggered polyneuropathy. In fact, 
half of all affected patients continued to suffer from symptoms of disabling CIPN after 
completion of HDCT treatment. Previous reports suggested that bortezomib (or vinorelbine-) 
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induced neuropathy was predominantly reversible after drug discontinuation within two to 
four months (Argyriou et al, 2008; Koeppen et al, 2014; Mohty et al, 2010). In contrast, 
improvement of CIPN in our cohort remained incomplete in a significant proportion of 
patients. In the absence of effective treatment modalities for CIPN, prevention of severe 
CIPN remains an important goal of induction treatment in myeloma patients (Cavaletti et al, 
2010; Mantyh et al, 2006; Stubblefield et al, 2009). 
This study was not powered to evaluate the effect of the development of CIPN on 
response and survival rates. In fact, we observed no differences in response and survival 
rates between myeloma patients with and without CIPN. However, developing CIPN can 
affect dosing, duration and the chemotherapy composition of later myeloma treatment 
thereby affecting response to treatment (Cavaletti et al, 2010; Mantyh et al, 2006; 
Stubblefield et al, 2009). Consequently, longer follow-up of a larger cohort may be required 
to ultimately provide answers to these issues. However, our data suggest that gemcitabine 
represents a promising alternative candidate to replace neurotoxic vinorelbine 
chemomobilization. Consequently, we initiated a randomized prospective trial comparing 
vinorelbine and gemcitabine mobilization chemotherapy in myeloma patients, and this trial 
may ultimately identify a novel role for gemcitabine as a non-neurotoxic and effective stem 
cell mobilization regimen in myeloma patients.  
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TITLES AND LEGENDS TO FIGURES  
 
Figure 1: A) Kaplan-Meier curves are depicted for the relapse-free survival (RFS) and B) for 
the overall survival (OS) of the entire study cohort. 
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  Table 2: Mobilization and transplantation. 
  
    
  
gemcitabine chemotherapy  + G-
CSF, n (%) 
24 (100) 
  one day of apheresis 19 (79) 
  two days of apheresis 5 (21) 
  1st apheresis at day 8 16 (67) 
  1st apheresis at day 9 7 (29) 
  1st apheresis at day 10 1 (4) 
     median (mean) 8 (8.38 ± 0.57) 
  duration of apheresis, mean, minutes 269.71 ± 91.27 
     median, minutes (range) 285 (70 - 420) 
 mean blood volume processed, liters 26.2 
    median, liters (range) 25.3 (13.5 – 33.9) 
  leukocytes at apheresis 
a
, mean (G/l) 33.80 ± 12.94 
     median (range) 34.4 (7.90 - 55.6) 
  peripheral CD34-Wert at apheresis 
a
 
 
     mean (x 10
 9
 / ml PB) 56.3 ± 38.1 
     median, x 10 6 / ml PB (range) 50.5 (4.4-122.4) 
  % CD34 leukocytes at apheresis 
a
  
 
     mean 0.19 ± 0.32 
     median (range) 0.14 (0.02 - 0.68) 
  total collected CD34+ x 10
6
 / kg b.w.
d
 
 
     mean 10.09 ± 6.61 
     median (range) 9.51 (4.95 - 19.2) 
 patients with > 5 x 10
6
 / kg CD34+ 23 (96) 
    cells after the 1
st
 day of apheresis  
  transfused CD34+ x 10
6
 / kg b.w.
d
   
     mean 3.51 ± 0.97 
     median (range) 3.4 (2.0 - 5.4) 
  first day of ANC
b
 > 0,5x109/L - n (%) 
 
     day 11 14 (58) 
     day 12 9 (38) 
     day 13 1 (4) 
     mean 11.46 ± 0.58 
     median (range) 11 (11 - 13) 
  first day of Plts
c
 > 20x109/L - n (%) 
 
     days 10-12 5 (21) 
     day 13 8 (33) 
     days 14-15 9 (38) 
     >day 15 2 (8) 
     mean 13.63 ± 2.27 
     median (range) 13 (9 - 21) 
  first day of Plts
c
 > 100x109/L - n (%) 
 
     ≤ day 20                   13 (54) 
     days 20-30 8 (33) 
     >day 30 3 (12) 
     mean 22.04 ± 5.88 
     median (range) 20 (15 - 40) 
___________________________________________________________________ 
 
a 
at the first day of apheresis; 
b 
ANC: absolute neutrophil count; 
c 
Plts; platelets; in the absence for transfusions in the previous 
three days; 
d 
b.w.: body weight. 
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